Post by BioVendor Group

🚨 Hepatitis E affects millions every year, yet it often remains underestimated   In 2021, an estimated 19 million acute HEV infections occurred worldwide. The infection can lead to severe outcomes, particularly in high-risk groups such as pregnant women and immunocompromised patients, making timely and accurate laboratory diagnosis essential.   To support HEV diagnostics, we introduce recomCLIA HEV IgG and recomCLIA HEV IgM kits, developed in collaboration with MIKROGEN GmbH, a partner of our fully automated CLIA solution.    Why recomCLIA HEV kits? ▪️ Detection of both IgM and IgG antibodies, aligned with clinical practice guidelines ▪️ Accurate results from early immune response through later stages of disease ▪️ Reliable detection of travel-associated and zoonotic cases ▪️ Excellent diagnostic performance with WHO-standardized calibration ▪️ Ready-to-use kits optimized for KleeYa® 👉 Explore the leaflet below to learn more. Detecting HEV can be challenging, and serological assays play a key role in diagnosis and infection staging. The initial immune response involves a rise in anti-HEV IgM, typically detectable for 3–12 months, followed by a longer-lasting IgG response detectable for over a year. From acute infections to suspected travel-related cases, recomCLIA HEV assays help laboratories deliver reliable results while improving workflow efficiency. #CLIA #KleeYa #hepatitisE #HEV #biotechnology #diagnostics #BioVendor